secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K/A
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001104659-25-055078
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 9.01, 1.01, 5.02, 3.02, 4.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma completes de-SPAC business combination, files Q1 2025 financials
--------------------------------------------------------------------------------

- Business combination closed April 30, 2025; combined company trades on Nasdaq as LIMN and LIMNW.
- Public stockholders redeemed 59,844 shares for ~$702k (~$11.74/share).
- Liminatus is pre-revenue, pre-clinical; net loss of $3.5M in FY2024, $5.0M in FY2023, accumulated deficit $28.7M.
- Amendment adds unaudited Q1 2025 financial statements of Liminatus and Iris; specific results not summarized in filing.
- Enterprise value of Liminatus set at $175M; 17,500,000 common shares issued to former Liminatus securityholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925055078/0001104659-25-055078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925055078/tm2516317d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-055078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer